Enrolling by invitationPhase 3NCT04905693
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- United Therapeutics
- Intervention
- Inhaled Treprostinil(drug)
- Enrollment
- 1850 target
- Eligibility
- 40 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- The University of Alabama at Birmingham, Birmingham, Alabama, United States
- Clinical Trials Center of Middle Tennessee, Franklin, Arizona, United States
- Banner University Medical Center-Phoenix, Phoenix, Arizona, United States
- St. Joseph's Hospital and Medical Center - Norton Thoracic Institute, Phoenix, Arizona, United States
- University of Arizona, Tucson, Arizona, United States
- UC San Diego Health, La Jolla, California, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- NewportNativeMD, Inc, Newport Beach, California, United States
- Palmtree Clinical Research, Inc., Palm Springs, California, United States
- UC Davis Health Medical Center, Sacramento, California, United States
- University of California San Francisco, San Francisco, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- National Jewish Health, Denver, Colorado, United States
- University of Florida Health at Shands, Gainesville, Florida, United States
- Ascension St. Vincent's, Jacksonville, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04905693 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGNANCT07466420Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.Katerina M. Antoniou
- RECRUITINGPHASE3NCT07299695Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary FibrosisArgyrios Tzouvelekis
- RECRUITINGPHASE2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics